Generation of breast cancer stem cells through epithelial-mesenchymal transition.

Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. · 2008

Read Generation of breast cancer stem cells through epithelial-mesenchymal transition. by Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2492808.txt.

Introduction

Morel and colleagues published this breast cancer study in 2008. It asks whether a process called epithelial-mesenchymal transition, or EMT, can create cancer stem cells. Cancer stem cells are the small set of tumor cells thought to start and sustain a tumor. EMT is a shift that lets settled cells become mobile and spread.

The team used a mammary tumor progression model built from human breast cells. Turning on the Ras-MAPK pathway, a chain of growth signals inside cells, produced cells with stem-like and tumor-forming traits. The authors show that switching on EMT drove this change. Cells gained the cancer stem cell character as they passed through the transition, linking the spread process to the birth of tumor-starting cells.

Catalog record

CREATORMorel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2492808

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition By Anne-Pierre Morel, Marjory Lièvre, Clémence Thomas, George Hinkal, Stéphane Ansieau, Alain Puisieux, Juha Klefstrom Published in: PLoS ONE DOI: 10.1371/journal.pone.0002888 ABSTRACT Abstract Recently, two novel concepts have emerged in cancer biology: the role of so-called “cancer stem cells” in tumor initiation, and the involvement of an epithelial-mesenchymal transition (EMT) in the metastatic dissemination of epithelial cancer cells. Using a mammary tumor progression model, we show that cells possessing both stem and tumorigenic characteristics of “cancer stem cells” can be derived from human mammary epithelial cells following the activation of the Ras-MAPK pathway. The acquisition of these stem and tumorigenic characters is driven by EMT induction. INTRODUCTION A growing body of evidence supports the notion that only a small subset of cells within a tumor, termed cancer stem cells (CSCs) or tumor-initiating cells, are capable of both tumor initiation and sustaining tumor growth [1]. Two basic arguments underlie the hypothesis that cancer stem cells originate from normal tissue stem cells. First, as tumor development is believed to result from the sequential and progressive accumulation of genetic abnormalities, adult stem cells appear to be ideal initial targets for malignant transformation due to their long lifespans. Second, CSCs share several properties with normal stem cells, such as their capacity for self-renewal and their ability to differentiate [2], [3]. The notion of a stem cell origin of cancer was first introduced in the context of hematological malignancies. This hypothesis has been supported by accumulating evidence in both chronic and acute leukemias [4]–[6]. Additionally, committed hematopoietic progenitor cells, with no inherent self-renewal properties, can be induced to generate cells capable of initiating and maintaining leukemias using leukemogenic fusion proteins [7]–[10], indicating that there is no absolute prerequisite for genetic mutation of normal stem cells. Over the past few years, candidate cancer stem cells have been identified in a variety of human malignancies including leukemias and a number of solid tumors such as glioblastomas, medulloblastomas and carcinomas [11]–[24]. Breast cancer is the first human carcinoma for which a putative cancer stem cell subpopulation has been isolated [25]. Using in vitro-separated tumorigenic cells from malignant human breast cancer-derived pleural effusions, Al Hajj and colleagues isolated a cell population characterized by high CD44 expression and low or undetectable levels of CD24 (CD44+CD24−/low) [25]. These cells were highly tumorigenic when injected into immunocompromised NOD/SCID mice and shared classic features of normal stem cells, including the capacity for self-renewal and generation of heterogeneous progeny [25]. The stem/progenitor cell phenotype of these cells was further refined by the Daidone group, who were able to grow mammospheres from single-cell suspensions obtained from the dissociation of primary breast tumors [3]. Mammospheres are non-adherent spherical cell clusters obtained in selective culture conditions, that have been shown to be enriched in mammary stem/progenitor cells [26]. The vast majority of cells in culture were CD44+CD24−/low, and 10 to 20% of these retained the ability to self-renew [3]. Congruent with previously reported experiments using models of hematopoietic malignancies [7]–[10], transformed breast cancer cells were obtained in vitro by introducing a series of oncogenes and cancer-associated genes into normal primary human mammary epithelial cells. This experimental system starts with primary human mammary epithelial cells (HMECs), that undergo sequential retroviral-mediated expression of the telomerase catalytic subunit (giving rise to HMEC/hTERT cells), SV40 large T and small t antigens (HMLE cells) and an oncogenic allele of H-Ras, H-RasV12 (HMLER cells) [27]. Using this model, we demonstrate that CD44+CD24−/low cells possessing stem-like properties can be generated from CD44lowCD24+ non-tumorigenic mammary epithelial cells through activation of the Ras/MAPK signaling pathway and can be accelerated by EMT induction. RESULTS To determine the potential origin of tumorigenic CD44+CD24−/low cells, we implemented a model of human breast cancer progression described by Elenbaas et al. [27] (Figure 1A). The Weinberg's group showed that HMLER cells (HMECs overexpressing hTERT, SV40 T/t and H-RasV12) were tumorigenic when injected subcutaneously or into the mammary glands of immunocompromised mice, suggesting the possible generation of cancer stem cells. To test this hypothesis, we analyzed the capabilities of the different cell populations (HMECs, HMEC/hTERT, HMLE and HMLER) to grow as non-adherent mammospheres, a property associated with mammary stem/progenitor cells [3], [26]. In contrast with HMECs, HMEC/hTERT and HMLE cells (Figure 1B–D), only HMLER cells grew as non-adherent clusters, suggesting that they displayed both tumorigenic and stem-like properties (Figure 1E). We further analyzed the phenotype of the different HMEC-derived cell lines (expanded in adherent conditions) by fluorescence-activated cell sorting (FACS) using CD44 and CD24 as markers (Figure 1F–I). HMECs and HMEC/hTERT immortalized mammary epithelial cells were CD44lowCD24+ (subsequently referred to as CD24+) and CD44+CD24−/low cells (subsequently referred to as CD24−) were totally undetectable in both cell populations (Figures 1F and 1G). The additional introduction of oncogenes was associated with the appearance and progressive increase of CD24− cells which accounted for 1.4% of HMLE cells and more than 65% of HMLER cells (Figures 1H and 1I). Consistent with the report that several components of the Ras/MAPK pathway are present in the expression profile of CD24− cancer cells [28], this observation suggested that cancer stem cells could be generated in response to the activation of specific signal transduction pathways. [Figure: Characterization of the different steps of the in vitro model of HMEC transformation.(A) Schematic representation of the successive steps of the transformation. (B,C,D,E) Evaluation of the ability of HMEC-derived cell lines to grow as non-adherent mammospheres. Scale bars = 100 µm. FACS analysis of CD24 and CD44 markers in HMEC-derived cell lines (F,G,H,I). B and F: Primary Human Mammary Epithelial Cell, (HMECs); C and G: hTERT- immortalized HMECs (HME); D and H: HME expressing SV40 small t and large T antigens (HMLE); E and I: H-RasV12-infected HMLE cells (HMLER).] This hypothesis was further investigated by studying using FACS analysis the emergence of CD24− cells following retroviral expression of H-RasV12 in HMLE cells. Whereas this cell population remained low (<2%) in uninfected cells, mutant Ras expression caused its progressive accumulation from 3.2% at day 5 following infection, 10.1% at day 24, 32.1% at day 30, to 65.4% at day 55 (Figure 1I and data not shown). This observation cannot be interpreted as a consequence of an enrichment of a rare subpopulation of cells displaying growth advantage because CD24− and CD24+ cells showed similar proliferation potential, as demonstrated by the methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay (data not shown). Of note, the length of time necessary for the emergence of CD24− cells following H-RasV12 introduction is consistent with the initial observation by Elenbaas and colleagues that the tumorigenicity of HMLER cells was associated with the occurrence of secondary events [27]. In order to determine the origin of CD24− cells, we performed cell sorting experiments and single-cell cloning assays following retroviral expression of H-RasV12 in HMLE cells. After sorting of CD24− and CD24+ populations, CD24+ cells were seeded onto 96-well plates under limiting dilution cloning conditions in order to isolate single cells (day 30 post-infection). After three weeks of cell growth, 35 independent individual clones were isolated and characterized. Whereas 47% of the clones were fully composed of CD24+ cells, 33% displayed a heterogeneous population of CD24+ and CD24− cells, and 19% were homogeneous for CD24− cells. These observations demonstrate

Read the complete text